P&G's Indian OTC wellness arm selling vitamin/mineral/supplement brands: Neurobion, Evion, Livogen.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 890 | 687 | 600 | 734 | 522 | 520 | 603 | 508 |
| Borrowings | 0 | 8 | 3 | 12 | 10 | 8 | 6 | 9 |
| Other Liabilities | 269 | 275 | 269 | 338 | 247 | 250 | 268 | 308 |
| Total Liabilities | 1.2k | 986 | 888 | 1.1k | 794 | 794 | 894 | 841 |
| AssetsFixed Assets | 101 | 104 | 112 | 144 | 128 | 116 | 106 | 102 |
| CWIP | 21 | 39 | 41 | 32 | 6 | 11 | 13 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1.1k | 843 | 736 | 925 | 660 | 667 | 776 | 726 |
| Total Assets | 1.2k | 986 | 888 | 1.1k | 794 | 794 | 894 | 841 |
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | — | 235 | 247 | 170 | 236 | 228 | 169 | 338 |
| Cash from Investing | — | 165 | -32 | -26 | -22 | -7 | 10 | 1 |
| Cash from Financing | — | -883 | -387 | -289 | -98 | -418 | -235 | -344 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | 212 | 196 | 132 | 198 | 207 | 168 | 323 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (36.2×) and current (31.7×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 10.8% growth and a 32× exit, ₹6244 only delivers your return if you pay ₹4,546. The price is currently baking in 17% growth.
EPS grows 10.8%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 10.8% | 218.21 |
| FY28 | 10.8% | 241.78 |
| FY29 | 10.8% | 267.89 |
| FY30 | 10.8% | 296.82 |
| FY31 | 10.8% | 328.88 |
| FY32 | 8.4% ·fade | 356.50 |
| FY33 | 6.0% ·fade | 377.89 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.